Open Access
Subscription or Fee Access
Health Care Worker’s Attitude and Hydroxychloroquine usage in a Tertiary Care Centre at Capital City of India during Early Phase of COVID 19
Abstract
Introduction: COVID 19 outbreak created apprehension and anxiety across the world because of the unpredicted and unexplained health consequences. There was a lot of scientific discussion happening among medical experts regarding the usage of Hydroxychloroquine (HCQ) as a prophylactic drug.
Methods: A cross sectional online survey was conducted among 180 Health Care Workers (HCWs) at Institute of Liver and Biliary Sciences, New Delhi, from April 2020 to May 2020 adopting a convenient sampling technique. Researcher developed five 5-point attitude scale was used which also included the demographic details of the subjects. The aim was to find the attitude of health care workers including nurses, doctors and paramedical staff.
Results: 79.9% subjects took Hydroxychloroquine for prophylaxis voluntarily. Majority of the participants were nurses (85.2%) with a female preponderance. The study revealed that majority (82.7%) had neutral attitude towards the usage.
Conclusion: HCQ is still being used as a prophylactic drug preventing the contractility of COVID 19 outbreak along with other standard precaution. There is a lack of conclusive evidence regarding the usage of HCQ as a prophylactic drug in the prophylaxis treatment of COVID 19 infection.
References
National Taskforce for COVID-19. (2020 Mar). Advisory on the use of hydroxy-chloroquine as prophylaxis for SARS-CoV-2 infection. [Online] Available from https://www.mohfw.gov.in/pdf/AdvisoryontheuseofHydroxychloroquinasprophylaxisforSARSCoV2infection.pdf
Sahaj Rathi, Pranav Ish, et al. Chloroquine or hydroxychloroquine for prophylaxis of COVID-19. Lancet. 2020; 3099(20): 30296–6.
Bhattacharyya D, Raizada N, et al. (2020 Jun). Chemoprophylaxis of COVID-19 with hydroxychloroquine - a study of health care workers attitude, adherence to regime and side effects. [Online] Available from: https://www.medrxiv.org/content/10.1101/2020.06.11.20126359v1
Noël F, Lima J. Pharmacological aspects and clues for the rational use of Chloroquine/Hydroxychloroquine facing the therapeutic challenges of COVID-19 pandemic. Lat Am J Clin Sci Med Technol. 2020; 2(1): 28–33.
Dan Zhou S-MDQT. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. Oxford Academic, J Antimicrob Chemother. 2020; 75(7): 1667–1670.
Driggin E, Madhavan MV, et al. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems during the COVID-19 Pandemic. J Am Coll Cardiol. 2020; 75(18): 2352–2371.
Ponticelli C, Moroni G. Hydroxychloroquine in systemic lupus erythematosus (SLE). Expert Opin Drug Saf. 2017; 16(3): 411–419.
Ochsendorf FR, Runne U. Chloroquine and hydroxychloroquine: Side-effect profile of important drugs. Hautarzt. 1991; 42(3): 140–6.
Gupta A, Kakkar R. Managing a covid 19 patient at different health care and field level settings. Indian J Community Heal. 2020; 32(2): 188–195.
Patrì A, Fabbrocini G. Hydroxychloroquine and ivermectin: A synergistic combination for COVID-19 chemoprophylaxis and treatment? J Am Acad Dermatol. 2020; 82(6): e221.
Napoli PE, Nioi M. Global Spread of Coronavirus Disease 2019 and Malaria: An Epidemiological Paradox in the Early Stage of A Pandemic. J Clin Med. 2020; 9(4): 1138.
Al-Kofahi M, Jacobson P, et al. Finding the dose for hydroxychloroquine prophylaxis for COVID-19; the desperate search for effectiveness. Clin Pharmacol Ther. 2020; 108(4): 766–769.
Parel JT, Varshney M, et al. Feeling the Early Impact of COVID-19 Pandemic: Mental Health of Nurses in India. J Depress Anxiety. 2020; 9(5): 381.
Varshney M, Parel JT, et al. Initial psychological impact of COVID-19 and its correlates in Indian Community: An online (FEEL-COVID) survey. PLoS One. 2020; 15(5): e0233874.
Refbacks
- There are currently no refbacks.